☆
4.7
Meeting Abstract
SAFETY AND EFFICACY OF LY3015014, A NEW MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) WITH AN INHERENTLY LONGER DURATION OF ACTION, IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING, PHASE 2 STUDY
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
导出引文
分享论文
评价这篇论文
主要评分表示论文的整体质量水平。次要评分独立反映论文的优点或缺点。
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now